285 related articles for article (PubMed ID: 18234282)
1. The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders.
Wasco MJ; Fullen D; Su L; Ma L
Hum Pathol; 2008 Apr; 39(4):557-63. PubMed ID: 18234282
[TBL] [Abstract][Full Text] [Related]
2. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
4. Abnormal activator protein 1 transcription factor expression in CD30-positive cutaneous large-cell lymphomas.
Mao X; Orchard G; Russell-Jones R; Whittaker S
Br J Dermatol; 2007 Nov; 157(5):914-21. PubMed ID: 17725669
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous lymphocyte antigen expression in benign and neoplastic cutaneous B- and T-cell lymphoid infiltrates.
Magro CM; Dyrsen ME
J Cutan Pathol; 2008 Nov; 35(11):1040-9. PubMed ID: 18681860
[TBL] [Abstract][Full Text] [Related]
6. Clusterin expression correlates with stage and presence of large cells in mycosis fungoides.
Chandra P; Plaza JA; Zuo Z; Diwan AH; Koeppen H; Duvic M; Medeiros LJ; Prieto VG
Am J Clin Pathol; 2009 Apr; 131(4):511-5. PubMed ID: 19289586
[TBL] [Abstract][Full Text] [Related]
7. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases.
Saggini A; Gulia A; Argenyi Z; Fink-Puches R; Lissia A; Magaña M; Requena L; Simonitsch I; Cerroni L
Am J Surg Pathol; 2010 Aug; 34(8):1168-75. PubMed ID: 20661014
[TBL] [Abstract][Full Text] [Related]
8. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides.
Lu D; Duvic M; Medeiros LJ; Luthra R; Dorfman DM; Jones D
Am J Clin Pathol; 2001 Mar; 115(3):413-21. PubMed ID: 11242798
[TBL] [Abstract][Full Text] [Related]
9. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
10. BCL2 and JUNB abnormalities in primary cutaneous lymphomas.
Mao X; Orchard G; Lillington DM; Child FJ; Vonderheid EC; Nowell PC; Bagot M; Bensussan A; Russell-Jones R; Young BD; Whittaker SJ
Br J Dermatol; 2004 Sep; 151(3):546-56. PubMed ID: 15377339
[TBL] [Abstract][Full Text] [Related]
11. Clusterin expression in cutaneous CD30-positive lymphoproliferative disorders and their histologic simulants.
Olsen SH; Ma L; Schnitzer B; Fullen DR
J Cutan Pathol; 2009 Mar; 36(3):302-7. PubMed ID: 19220628
[TBL] [Abstract][Full Text] [Related]
12. The significance of MUM1/IRF4 protein expression and IRF4 translocation of CD30(+) cutaneous T-cell lymphoproliferative disorders: a study of 53 cases.
Kiran T; Demirkesen C; Eker C; Kumusoglu H; Tuzuner N
Leuk Res; 2013 Apr; 37(4):396-400. PubMed ID: 23332472
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases.
Kikuchi A; Nishikawa T
Arch Dermatol; 1997 Jul; 133(7):829-33. PubMed ID: 9236520
[TBL] [Abstract][Full Text] [Related]
14. Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
Greisser J; Palmedo G; Sander C; Kutzner H; Kazakov DV; Roos M; Burg G; Kempf W
J Cutan Pathol; 2006 Nov; 33(11):711-5. PubMed ID: 17083688
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II.
Paulli M; Berti E
Haematologica; 2004 Nov; 89(11):1372-88. PubMed ID: 15531460
[TBL] [Abstract][Full Text] [Related]
16. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
17. Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay.
Yagi H; Seo N; Ohshima A; Itoh T; Itoh N; Horibe T; Yoshinari Y; Takigawa M; Hashizume H
Am J Surg Pathol; 2006 Sep; 30(9):1111-9. PubMed ID: 16931956
[TBL] [Abstract][Full Text] [Related]
18. Pathobiology of CD30+ cutaneous T-cell lymphomas.
Kadin ME
J Cutan Pathol; 2006 Feb; 33 Suppl 1():10-7. PubMed ID: 16412208
[TBL] [Abstract][Full Text] [Related]
19. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
[TBL] [Abstract][Full Text] [Related]
20. Histopathological aspects and differential diagnosis of CD8 positive lymphomatoid papulosis.
Marschalkó M; Gyöngyösi N; Noll J; Károlyi Z; Wikonkál N; Hársing J; Kuroli E; Csomor J; Matolcsy A; Sarolta K; Szepesi Á
J Cutan Pathol; 2016 Nov; 43(11):963-973. PubMed ID: 27461449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]